Form 8-K · Current report
Stryker Corporation 8-K, filed Oct 29, 2026
- Filed
- CIK
- 0000310764
- Accession no.
- 0000310764-26-000059
Summary
Stryker reported third quarter 2026 net sales of $6.5 billion, up 7.7% on both a reported and organic basis, with adjusted earnings per diluted share up 10.3% to $3.52 and reported EPS down 11.7% to $1.96. Chair and CEO Kevin A. Lobo said the quarter's performance fell short of the company's expectations, and Stryker updated full-year 2026 guidance to organic net sales growth of 6.5% to 7.0% and adjusted EPS of $14.80 to $14.90.
Key points
- Stryker repurchased $1.0 billion of its common stock in the third quarter of 2026, and in October 2026 its board approved a $3.0 billion increase to its existing share repurchase program.
- MedSurg and Neurotechnology net sales rose 9.2% to $3.7 billion and Orthopaedics net sales rose 5.7% to $2.9 billion.
- Adjusted operating income margin increased 60 basis points to 26.2%, while reported operating income margin was 15.9%.
- Reported net earnings were $753 million, down 12.3%, and the company scheduled a conference call on October 29, 2026 to discuss the quarter.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION Stryker Corporation issued a press release on October 29, 2026 announcing its third quarter 2026 operating results. A copy of this press release is attached hereto as Exhibit 99.1. The information furnished in this report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.